GleamWall
中文EN

ACTU ACTUATE THERAPEUTICS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1652935 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY23.4%
TTM EPS YoY-323.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-364.7%
ROA-176.4%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets125.1%
Debt / equity—
Current ratio0.73x
Interest coverage-925.44x

Cash quality & payout

Operating cash flow / net income0.87x
Accruals ratio-22.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31
Income statement
Revenue———
R&D expense$10.29M$18.68M$21.71M
SG&A expense$12.20M$6.48M$3.27M
Operating income-$22.50M-$25.16M-$24.97M
Interest expense$20,250$18,717$43,641
Income tax$800$800$0
Net income-$22.23M-$27.29M-$24.74M
EPS (basic)-1.06-3.26-17.24
EPS (diluted)-1.06-3.26-17.24
Weighted avg. shares (diluted)21.02M8.37M1.43M
Balance sheet
Cash & equivalents$13.16M$8.64M$2.96M
Current assets$13.64M$9.21M$3.00M
Total assets$14.04M$9.32M$3.00M
Current liabilities$5.71M$8.80M$6.92M
Total liabilities$6.11M$9.21M$8.44M
Shareholders' equity$7.92M$104,186-$99.63M
Shares outstanding23.25M19.53M1.69M
Cash flow statement
Operating cash flow-$19.21M-$21.84M-$21.63M
Financing cash flow$23.72M$27.53M$4.13M
Stock-based compensation$6.05M$2.00M$423,539

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-19 06:28.